American Society of Hematology

ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases.

  • Urge the Senate to Pass H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015

    Each year, physicians who treat Medicare beneficiaries are subject to significant payment cuts as a result of flaws in the SGR formula that is currently used to establish annual Medicare physician updates.  The House recently passed legislation that would repeal SGR formula and replace it with a 0.5 percent annual physician pay increase for the next five years.  However, the Senate adjourned for spring recess before considering the bill.  It is critical that Senators hear from their physician constituents about the need to pass the Medicare Access and CHIP Reauthorization Act of 2015 immediately upon their return from recess on April 13, in order to avoid large payment cuts for services provided in April.

  • Take Action to Support Funding for Medical Research

    Your Senators and Representative need to continue to hear from you about the impact that unpredictable funding and potential funding cuts will have on your research and the patients you treat and the need for them to recognize the value of biomedical research by investing in the NIH.

  • Urge Your Senators and Representative to Support the Cancer Drug Coverage Parity Act

    Legislation will soon be reintroduced in the U.S. House of Representatives and U.S. Senate that would ensure that patients enrolled in certain federally regulated health plans have access and insurance coverage for all anti-cancer regimens.

View all action alerts
  • New SGR Bill Released

    On March 19, the House of Representatives introduced a bill that would permanently address the SGR issue.  This bill largely follows the policy of the bill that was introduced by the committees of jurisdiction during the last Congress.  That bill, which ASH supported, eliminated the SGR update formula in favor of a new payment schedule.  Follow the link above to read more about the bill.

  • New Oncology Care Model Released by Center for Medicare and Medicaid Innovation

    On February 12, 2015, the Center for Medicare and Medicaid Innovation (CMMI) revealed the opportunity for practices to participate in a payment model dedicated the care of patients with cancer.  Although there will be additional details to finalize, CMMI would like practices to express interest in participating in the model by April 23, 2015, even though it will not begin paying with this method until 2016.  Click on the headline to read more.

  • ASH Comments on FDA Draft Guidance for Laboratory Developed Tests

    On January 30, ASH submitted comments on the Food and Drug Administration's (FDA) Draft Guidance  on Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs).  The Guidance Document proposes that FDA assert its regulatory authority and increase oversight of LDTs.  Click on the link above to read more about ASH's comments.

  • ASH Comments on NIH Single IRB Policy

    On January 28, The American Society of Hematology (ASH) submitted comments  on the National Institutes of Health's (NIH) Draft Policy to promote the use of a single Institutional Review Board (IRB) of record for domestic sites of multi-site clinical studies funded by NIH.  The draft NIH policy proposes that all NIH-funded, multi-site studies carried out in the United States, whether supported through grants, contracts, or the NIH intramural program, should use a single IRB.  Read more to learn about ASH's stance on the policy.

View all policy news
back to top